Importantly, recent reports have shown that RAS dimerization lead to a better activation of ERK [114], and that oncogenic mutations stabilize dimerization of KRAS, drive tumorigenesis and may also account for tumor resistance to MEK inhibitors [116,117]. The gene discussed is MAP2K7; the disease is neoplasm.